Table of contents
How We’ll Know This Worked
Executive Summary
By this point in the series, the case for change has already been made.
We have covered why prohibition underperforms, why a public health drug policy beats moral panic, why risk-based drug regulation is more honest than one-size-fits-all law, why the highest-risk lane belongs in a regulated pharmacy model, why treatment on demand matters, why youth protection has to be built into the design, why public safety gets sharper when it targets real harms, and why the black market drugs economy survives on policy gaps.
So this chapter asks the question that really matters after all of that:
What would success actually look like?
Not in slogans.
Not in vibes.
In measurable drug policy reform outcomes.
The baseline is ugly enough that the answer has to be concrete. Final CDC data show the United States still recorded 79,384 drug overdose deaths in 2024.[1] CDC also says 54.6 million people needed substance use treatment in 2022, but only 13.1 million received it.[2] NIDA says fewer than 1 in 5 people with opioid use disorder receive medications that reduce overdose risk and improve outcomes.[3] Those three numbers alone tell you why an overdose prevention policy, treatment on demand, and better addiction treatment outcomes are not optional metrics. They are the first scoreboard.
The rest of the scoreboard matters too. NCQA already has standardized measures for addiction treatment outcomes, including Initiation and Engagement of Substance Use Disorder Treatment (IET), Follow-Up After Emergency Department Visit for Substance Use (FUA), and Follow-Up After High-Intensity Care for Substance Use Disorder (FUI).[4][5][6] CDC’s DOSE system already tracks nonfatal overdose trends with standardized surveillance definitions across 49 states and the District of Columbia.[7] BJS shows the current jail system still cycles enormous numbers of people through custody, with 7.6 million admissions from July 2022 to June 2023 and 70% of the jail population unconvicted at midyear 2023.[8] That means the right drug policy reform outcomes are not mysterious. They are already measurable.
This chapter makes a simple argument:
• at 5 years, success means leading indicators are moving in the right direction
• at 10 years, success means systems and incentives have actually changed
• at 20 years, success means the new model is normal, durable, and harder to reverse than the old one ever was
That is what this post is for.
The Measurement Problem This Chapter Solves
The biggest mistake in this debate is acting like success means no one ever uses drugs again.
That is not a serious goal. It has never been a serious goal.
A real public health drug policy does not define success as zero use, zero relapse, zero crime, or zero disorder. It defines success as whether the system produces less death, less instability, less churn, and better addiction treatment outcomes than the system it replaced. That is why the right drug policy reform outcomes have to measure the world as it is, not the fantasy world prohibition always promised and never delivered. This is also the natural continuation of Part 16’s pilot-measure-scale framework, Part 23’s status-quo projection, and Part 30’s argument for measuring outcomes without building a punitive state.
So the measurement problem is not, “Can we prove perfection?”
It is, “Can we prove this is safer, fairer, and more effective than what we have now?”
That is the standard.
1. Drug Policy Reform Outcomes Start With the Right Baseline
If the baseline is fake, the evaluation will be fake too.
That is why serious drug policy reform outcomes start with current reality:
• overdose deaths [1]
• treatment need versus treatment received [2]
• medications for opioid use disorder access [3]
• nonfatal overdose trends [7]
• jail churn and conviction status [8]
• youth-use trends [9]
• legal versus illicit market share [10]
Those are not random categories. They are the minimum viable dashboard for a system that claims to be better.
A serious overdose prevention policy should be judged first on whether fewer people die and fewer people show up in emergency settings with nonfatal overdose events. CDC’s DOSE system already gives states and localities a way to monitor those trends using standardized definitions and discharge or syndromic surveillance data.[7] That means the country already has part of the measurement infrastructure it needs.
A serious public health drug policy should also be judged on whether more people actually get into treatment and stay there. That is where NCQA’s IET, FUA, and FUI measures become crucial. IET measures whether a new SUD episode results in treatment initiation within 14 days and engagement within 34 days.[4] FUA measures follow-up within 7 and 30 days after an emergency department visit for substance use or drug overdose.[5] FUI measures follow-up within 7 and 30 days after high-intensity care such as inpatient hospitalization, residential treatment, or withdrawal management.[6] These are exactly the kinds of addiction treatment outcomes that a serious system should publish.
And a serious reform model should not ignore the criminal-system baseline either. BJS reports that local jails held 664,200 people at midyear 2023, with 7.6 million admissions from July 2022 to June 2023, and that 70% of the jail population was unconvicted. BJS also reported the jail incarceration rate for Black U.S. residents at 552 per 100,000, compared with 155 per 100,000 for white residents.[8] That means incarceration reduction and health equity are not side issues. They belong in the baseline.
That is the starting line.
2. Five-Year Success: Overdose Prevention Policy and Treatment on Demand
At 5 years, success should be visible in the leading indicators, not just in speeches.
This is the stage where a good overdose prevention policy and real treatment on demand should begin to prove that the system is moving in the right direction.
At five years, success should mean:
fatal overdose deaths are falling from the pre-reform baseline [1]
nonfatal overdose emergency visits and inpatient discharges are falling in participating systems [7]
IET initiation and engagement rates are improving [4]
FUA follow-up after emergency visits is improving [5]
FUI follow-up after inpatient or residential care is improving [6]
more people receive medications for opioid use disorder [3]
That is how drug policy reform outcomes should work in the first phase. The question is not whether every deep social problem is solved in five years. The question is whether the policy has changed the direction of travel.
A serious treatment on demand system should, by five years, be able to show that more people are entering care quickly after overdose, after withdrawal management, or after a first treatment episode. That is why treatment on demand appears over and over in this series: it is one of the clearest ways to tell whether a reform model is real or just rhetorical. If people are still waiting too long when they are finally ready for help, the policy is not working well enough.[3][4][5][6]
At the same time, five-year success should not come at the cost of youth protection. NIDA reported in late 2024 that use of most drugs among adolescents remained low and stable, including a decline in cannabis use among 12th graders from 29.0% in 2023 to 25.8% in 2024, while cannabis vaping remained stable across grades.[9] That means one of the clearest early success tests is whether youth-use trends stay stable or improve even while adult systems become more honest and regulated. A policy that lowers adult harms but drives a new youth spike is not success.
So five-year success is not mystical.
It is a pattern:
• fewer deaths
• fewer repeat emergencies
• faster treatment on demand
• better addiction treatment outcomes
• stable or improved youth protection
3. Ten-Year Success: Public Health Drug Policy, Incarceration Reduction, and Public Safety
At 10 years, the question shifts.
Now the issue is no longer whether the first indicators moved. The issue is whether the new system changed institutions, incentives, and social defaults.
That is where public health drug policy has to start looking normal rather than experimental.
At ten years, success should mean:
the fatal overdose rate is sustainably lower than the old baseline [1]
treatment on demand is a standard operating expectation, not a pilot project [2][3][4][5][6]
addiction treatment outcomes show stronger initiation, stronger follow-up, and stronger retention [4][5][6]
jail admissions and the use of jails as default crisis containers are meaningfully lower [8]
racial gaps narrow, meaning health equity is improving rather than being deferred [8]
public safety metrics do not show that neighborhoods, roads, and workplaces became less governable
This is where incarceration reduction becomes one of the clearest long-term markers. The BJS baseline is already large enough that a serious system should be able to do better than 7.6 million admissions and a pretrial-heavy jail structure over time.[8] Ten-year success does not require pretending jail disappears. It requires showing that the new model sends fewer people through it for the same unresolved crisis.
Ten-year success should also show visible erosion of the illicit market. Health Canada’s 2024 Canadian Cannabis Survey offers a useful benchmark. Among past-year cannabis consumers, 72% reported purchasing from a legal source, only 3% reported using an illegal purchase source, and 67% said they always obtained cannabis from a legal or licensed source. Consumers cited convenience, price, and safe supply as their top purchase factors.[10] That does not mean every country or every product category will replicate Canada’s exact pattern. But it does show that a legal system can win share from black market drugs if the legal option is easier, safer, and trusted.
This is also where risk-based drug regulation proves itself. By ten years, success should mean the public no longer hears “drug legalization” and imagines one giant undifferentiated market. It should mean the lower-risk lane, the highest-risk regulated pharmacy model, public safety, accountability, and youth protection all make sense as parts of one coherent system.
That is what ten-year success looks like.
4. Twenty-Year Success: Drug Policy Reform Outcomes Become the New Common Sense
At 20 years, success stops looking like a reform project and starts looking like normal governance.
That is when the deepest drug policy reform outcomes should be visible.
At twenty years, success should mean:
the country no longer treats mass overdose as a permanent background condition
public health drug policy is the normal frame for addiction, not a minority position
treatment on demand is expected in the same way emergency care is expected
addiction treatment outcomes are transparent enough that funding follows performance more than rhetoric
risk-based drug regulation is ordinary, not exotic
the regulated pharmacy model is accepted as the right lane for the highest-risk products
public safety enforcement focuses on violence, coercion, fraud, and actual dangerous behavior
black market drugs no longer dominate the spaces where legal and regulated systems have matured
This is also where health equity should be judged generationally, not cosmetically. If the country still has dramatically unequal overdose burdens, dramatically unequal treatment access, and dramatically unequal incarceration exposure after twenty years, then the reform was not deep enough. The point of long-term drug policy reform outcomes is not simply lower averages. It is a system that distributes safety more fairly than the old one did.[2][8]
A twenty-year horizon should also show whether the public’s relationship to drug policy changed. If the issue is still governed mainly by panic, then the system did not mature. If the issue is governed by metrics, accountability, and ordinary institutional competence, then it did.
That is what success means at the generational scale.
5. The Dashboard: What We Should Publish Every Quarter
If this series has one recurring principle, it is this:
What does not get measured honestly will get manipulated politically.
That is why the quarterly dashboard matters.
A serious dashboard for drug policy reform outcomes should include five buckets.
A. Overdose Prevention Policy
• fatal overdose deaths [1]
• nonfatal overdose ED and inpatient rates [7]
• repeat overdose events [7]
• naloxone distribution and use [7]
• geographic hot spots [7]
B. Addiction Treatment Outcomes
• IET initiation within 14 days [4]
• IET engagement within 34 days [4]
• FUA 7-day and 30-day follow-up [5]
• FUI 7-day and 30-day follow-up [6]
• medication access for opioid use disorder [3]
C. Public Safety
• impaired-driving patterns
• workplace safety incidents in affected sectors
• violent trafficking cases
• diversion incidents
• youth sales violations
D. Incarceration Reduction and Health Equity
• jail admissions [8]
• pretrial detention share [8]
• racial disparities in incarceration [8]
• disparities in overdose burden [2]
• disparities in treatment initiation and follow-up [4][5][6]
E. Market and Trust
• legal versus illegal market share where measurable [10]
• access to regulated supply [10]
• privacy complaints and compliance where relevant
• patient trust and treatment uptake
• community confidence
That dashboard is the difference between a reform story and a reform system.
6. What Success Does Not Mean
This part matters because people will try to rig the test.
Success does not mean:
• zero drug use
• zero relapse
• zero black market activity
• zero crime
• zero youth exposure ever
• unanimous public agreement
Those are fantasy standards.
A serious public health drug policy should be judged against the real alternative: the status quo it replaced. That is the only honest frame. If the new system produces fewer deaths, faster treatment on demand, better addiction treatment outcomes, stronger youth protection, more accountability, better public safety, and visible incarceration reduction, then it is working even if some problems remain.
That is not lowering the bar.
That is refusing a fake bar.
The Bottom Line
Part 36 is the measurement chapter for the whole series.
If this works, we should be able to prove it.
The proof will not come from one magical statistic. It will come from a pattern of drug policy reform outcomes that becomes harder to deny over time:
• an overdose prevention policy that keeps driving deaths and repeat emergencies down
• treatment on demand that turns readiness into actual entry
• stronger addiction treatment outcomes measured through real initiation, follow-up, and retention
• a durable public health drug policy that stops treating punishment as the main intervention
• a system built on risk-based drug regulation, a regulated pharmacy model where risk is highest, sharper public safety, more accountability, stronger youth protection, less black market drugs power, more incarceration reduction, and better health equity
That is what success looks like at 5, 10, and 20 years.
And if a reform model cannot tell you how it will know it worked, it is not ready.
Frequently Asked Questions
What are the most important first indicators to watch?
The most important early indicators are an improved overdose prevention policy, faster treatment on demand, better initiation and follow-up rates, and a sustained decline in fatal and nonfatal overdose burden.[1][4][5][6][7]
Why use addiction treatment outcomes instead of just counting treatment slots?
Because addiction treatment outcomes tell you whether care actually begins, continues, and reconnects after crisis. NCQA’s IET, FUA, and FUI measures are better than simple slot counts because they measure movement through the system, not just capacity on paper.[4][5][6]
Why does treatment on demand matter so much in the 5-year and 10-year windows?
Because treatment on demand is one of the clearest signs that the system changed from punishment theater to actual intervention. If help is still hard to reach when people are finally ready, the reform is still too weak.[2][3]
What does success look like for youth protection?
It means no sustained rise in youth use and no new product environment that makes access easier for minors. NIDA’s 2024 adolescent-use data provide a baseline for that test.[9]
How do we know the black market is actually shrinking?
One way is to measure whether people increasingly choose legal, regulated sources over illicit ones. Health Canada’s 2024 cannabis survey shows that this is measurable and that convenience, price, and safe supply all matter.[10]
References
[1] Centers for Disease Control and Prevention, National Center for Health Statistics. U.S. Life Expectancy Hits Record High as Drug Overdose Deaths Decline in 2024. https://www.cdc.gov/nchs/pressroom/releases/20260129.html
[2] Centers for Disease Control and Prevention. Stigma Reduction. https://www.cdc.gov/stop-overdose/stigma-reduction/index.html
[3] National Institute on Drug Abuse. Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
[4] NCQA. Initiation and Engagement of Substance Use Disorder Treatment (IET). https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/initiation-and-engagement-of-substance-use-disorder-treatment-iet/
[5] NCQA. Follow-Up After Emergency Department Visit for Substance Use (FUA). https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/follow-up-after-emergency-department-visit-for-substance-use-fua/
[6] NCQA. Follow-Up After High-Intensity Care for Substance Use Disorder (FUI). https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/follow-up-after-high-intensity-care-for-substance-use-disorder-fui/
[7] Centers for Disease Control and Prevention. Nonfatal Drug Overdose Surveillance and Epidemiology (DOSE) System. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/about-dose-system.html
[8] Bureau of Justice Statistics. Jail Inmates in 2023 – Statistical Tables. https://bjs.ojp.gov/library/publications/jail-inmates-2023-statistical-tables/web-report
[9] National Institute on Drug Abuse. Reported use of most drugs among adolescents remained low in 2024. https://nida.nih.gov/news-events/news-releases/2024/12/reported-use-of-most-drugs-among-adolescents-remained-low-in-2024
[10] Health Canada. Canadian Cannabis Survey 2024: Summary. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2024-summary.html
[11] U.S. Department of Health & Human Services. Fact Sheet: 42 CFR Part 2 Final Rule. https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html
[12] Centers for Disease Control and Prevention. Prescription Drug Monitoring Programs (PDMPs). https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/prescription-drug-monitoring-programs.html
If you want to follow the full series as it publishes, visit the full Drug Legalization Series. If you prefer audio conversations on recovery, reentry, and purpose, check the podcast page. For program directors building reentry and transition programming, see ReturnPath reentry curriculum. For the personal story behind this work, read A Vision of Hope. To invite Andrew for a keynote or panel, see speaking.